Want to see HK:9989 full AI Analyst Report?
Top Page
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
(9989)
Select Model
Select Model
Rating:59Neutral
Price Target:
HK$4.50
▼(-13.29% Downside)
Action:Reiterated
Date:09/06/26
The score is primarily supported by solid cash generation and a conservative balance sheet, which help mitigate operating volatility. It is held back by weak recent profitability/returns and a demanding valuation (very high P/E), while technicals remain soft with the stock trading below major moving averages and a negative MACD.
Positive Factors
Conservative balance sheet
Moderate leverage and a substantial equity base provide financial resilience through operating volatility. Reduced leverage also preserves borrowing capacity and gives management greater flexibility to fund products, compliance, and growth without excessive balance-sheet strain.
Negative Factors
Recent revenue contraction
Recent revenue contraction signals weaker demand, pricing, or sales mix than the company previously achieved. If the decline persists, it could limit operating leverage, reduce funds available for development, and make sustained earnings improvement harder to achieve.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Moderate leverage and a substantial equity base provide financial resilience through operating volatility. Reduced leverage also preserves borrowing capacity and gives management greater flexibility to fund products, compliance, and growth without excessive balance-sheet strain.
Read all positive factors
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (9989) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$15.27B
Dividend Yield3.95%
Average Volume (3M)558.27K
Price to Earnings (P/E)71.8
Beta (1Y)0.96
Revenue Growth3.10%
EPS Growth-46.64%
CountryHK
Employees2,150
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.14
Shares Outstanding220,094,500
10 Day Avg. Volume445,050
30 Day Avg. Volume558,266
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)0.57
Price to Sales (P/S)1.25
P/FCF Ratio4.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.67
Revenue Forecast (FY)HK$6.64B
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a ...
How the Company Makes Money
Hepalink primarily makes money by selling pharmaceutical products and services across multiple parts of the heparin/anticoagulation value chain. Key revenue streams typically include: (1) Sales of heparin-based APIs: The company manufactures hepar...
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
72
Positive
Cash Flow
77
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.24B | 5.48B | 5.28B | 5.45B | 7.16B | 6.37B |
| Gross Profit | 1.75B | 1.74B | 1.76B | 1.80B | 2.33B | 2.03B |
| EBITDA | 351.83M | 846.59M | 1.20B | ― | 1.37B | 726.64M |
| Net Income | 202.88M | 349.49M | 646.74M | ― | 727.43M | 240.79M |
Balance Sheet | ||||||
| Total Assets | 16.31B | 16.63B | 17.34B | 19.20B | 20.81B | 19.11B |
| Cash, Cash Equivalents and Short-Term Investments | 3.55B | 2.83B | 2.56B | 2.27B | 3.45B | 3.93B |
| Total Debt | 2.89B | 2.11B | 2.98B | 3.78B | 6.46B | 5.65B |
| Total Liabilities | 4.33B | 4.55B | 5.14B | 7.22B | 8.41B | 7.58B |
| Stockholders Equity | 11.93B | 12.03B | 12.15B | 11.91B | 12.31B | 11.41B |
Cash Flow | ||||||
| Free Cash Flow | 1.42B | 1.59B | 1.99B | -46.66M | -979.03M | -200.49M |
| Operating Cash Flow | 1.50B | 1.71B | 2.19B | 398.22M | -756.61M | -6.63M |
| Investing Cash Flow | -1.11B | -872.75M | -415.05M | 1.22B | 249.84M | 719.93M |
| Financing Cash Flow | -936.24M | -1.09B | -2.14B | -1.21B | 329.56M | -501.08M |
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Technical Analysis
Negative
5.19
Price Trends
4.30
Negative
4.33
Negative
4.70
Negative
Market Momentum
-0.02
Positive
45.03
Neutral
33.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9989, the sentiment is Negative. The current price of 5.19 is above the 20-day moving average (MA) of 4.35, above the 50-day MA of 4.30, and above the 200-day MA of 4.70, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 45.03 is Neutral, neither overbought nor oversold. The STOCH value of 33.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9989.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$24.91B | 14.40 | 11.97% | 7.82% | -5.90% | -18.84% | |
68 Neutral | HK$27.80B | 5.99 | 7.92% | 4.85% | 7.94% | 52.83% | |
61 Neutral | HK$26.76B | 15.24 | 8.60% | 3.12% | 14.80% | -2.88% | |
59 Neutral | HK$15.27B | 71.85 | 1.67% | 3.95% | 3.10% | -46.64% | |
59 Neutral | HK$65.60B | 17.77 | 6.97% | 2.61% | 9.88% | 9.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$7.42B | 20.37 | 5.03% | 1.37% | 29.68% | ― |
* Healthcare Sector Average
HK:9989
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
4.21
-1.57
-27.19%
HK:0867
China Medical System Holdings
11.04
-3.10
-21.90%
HK:1513
Livzon Pharmaceutical Group
21.02
-14.13
-40.20%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
17.26
-9.47
-35.43%
HK:0460
Sihuan Pharmaceutical Holdings Group
0.80
-0.84
-51.47%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.49
-0.23
-4.81%
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Corporate Events
Hepalink convenes 2026 EGM to expand wealth management and credit lines
Aug 31, 2026
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has called its first extraordinary general meeting of 2026 for September 22 in Shenzhen, inviting shareholders of its H shares to vote on key financial management resolutions. The meeting will consi...
Hepalink Profit Slumps on Lower Revenue Despite Margin Improvement
Aug 28, 2026
Shenzhen Hepalink Pharmaceutical Group reported interim unaudited revenue of RMB2.56 billion for the six months ended June 30, 2026, an 8.2% decline from a year earlier, while profit attributable to shareholders fell 36.6% to RMB275.3 million. Des...
Hepalink Raises Wealth Management Fund Limit, Trims Guarantee Cap
Aug 28, 2026
Shenzhen Hepalink Pharmaceutical Group plans to raise the cap on its use of internal funds for purchasing wealth management products and managing cash flow from RMB2.5 billion to RMB3.5 billion, effective until its 2026 annual general meeting, to ...
Shenzhen Hepalink Sets Board Meeting to Review Interim Results and Dividend
Aug 14, 2026
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has scheduled a board meeting for August 28, 2026 to review and approve the Group’s interim results for the six months ended June 30, 2026, and to decide on the publication of those results.Th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.